Hair Loss Related to Taxotere
The number is overwhelming of breast cancer patients prescribed Docetaxel when receiving chemotherapy because of its vast popularity.
The medication, also sold as Taxotere in the marketplace, gained favor under false pretenses when women were guaranteed it was more lucrative than the alternatives on hand, and concealed adverse side-effects from the public.
As women sustained traumatic impacts to their body image due to permanent and severe hair loss related to Taxotere, the manufactured profited billions of dollars.Exploitation and Deceit of Taxotere
With hair loss related to Taxotere, approximately 300,000 women become diagnosed every year with breast cancer. Chemotherapy is a common and popular aspect of treatment plans geared to destroy cancer cells and prevent its spread.
Taxotere, for breast cancer treatment, is the most prescribed chemotherapy medication. The medication on the market is not the only medicine of its kind.
Among the most viable alternatives to Taxotere is Paclitaxel, medication which has been in the marketplace much longer.
Studies have confirmed that Pacilitaxel is as viable as Docetaxel, but on a weekly basis it needs to be administered.
There’s notoriety with Taxotere because women could opt instead to receive the medication every three weeks.
Sanofi-Aventis, the manufacturer of the drug, promised treatments less frequently by playing on the emotions of women, realizing how chemotherapy can be uncomfortable for some people.
The incentive for physicians to recommend Taxotere is that it is more efficient and convenient, to require fewer visits for the patient to achieve similar results.
Most of the physicians prescribing this medicine were not aware of its deleterious side effects, to assume that the effects were the same to what, under alternatives, women experience.
Although Sanofi-Aventis became aware of critical side effects connected to the medicine, they concealed information from the public eye, knowing women, if they knew the risks, would choose Taxotere.
Concealing this information has opened to liability claims the door because customers have a right to be aware of any likelihood for negative reactions before being sold medicine.
It is a known fact that hair loss is a typical side effect from the treatment of chemotherapy. In most cases, however, patients regrow lost hair not long after the end of treatments.
Approximately one in ten women with Taxotere as a prescription were alarmed to discover their hair failed to grow back.
This is referred to as alopecia; for decades, victims sustained this condition as the hair failed to grow back.
For hair loss related to Taxotere, thousands of women were angered to learn that the parent company wasn’t only aware of a likelihood the drug had for resulting in permanent hair loss, but that it marketed falsely the medicine as a more viable and convenient way to medicines which didn’t have the same effects.
Routinely physicians inform women when undergoing chemotherapy and radiation to expect hair loss, but they inform them also that their hair afterward is likely to grow back.